PBLS · Insider Trading
Parabilis Medicines, Inc. Common Stock
Every open-market purchase and sale reported by PBLS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Craig Tendler | Director | A | +20,294 deriv. | — |
| 2026-07-22 | RA Capital Healthcare Fund LP | Director | Buy | +1,222,965 | +$34.60M |
| 2026-06-29 | Soleus Capital Management, L.P. | 10%+ Owner | MIXED | +9,243,630 | +$134.97M |
| 2026-06-16 | Alan Sebulsky | Director | Buy | +17,500 | +$473.53K |
| 2026-06-15 | Alan Sebulsky | Director | Buy | +12,500 | +$250.00K |
| 2026-06-15 | Alexis Borisy | Director | C | +105,414 | — |
| 2026-06-15 | Edward M Fitzgerald | Director | C | +14,688 | — |
| 2026-06-15 | Rajeev M. Shah | Director | MIXED | +144,666,855 | +$2.12B |
| 2026-06-11 | Richard Klausner | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Alexis Borisy | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Barbara Weber | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Alan Sebulsky | Director | A | +39,792 deriv. | — |
| 2026-06-11 | Jake Simson | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Edward M Fitzgerald | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Krishna Yeshwant | Director | A | +20,215 deriv. | — |
| 2026-06-11 | Rajeev M. Shah | Director | A | +101,075 deriv. | — |
| 2026-06-11 | DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | C | +11,284,224 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RA Capital Healthcare Fund LP | Director | 26,444,713 | $661.91M |
| Rajeev M. Shah | Director | 26,285,093 | $657.92M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | 533,220 | $13.35M |
| Soleus Capital Management, L.P. | 10%+ Owner | 527,070 | $13.19M |
| Alexis Borisy | Director | 105,414 | $2.64M |
| Alan Sebulsky | Director | 25,935 | $649.15K |
| Edward M Fitzgerald | Director | 14,688 | $367.64K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PBLS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.